A Phase IIb Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs Ramucirumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms RAMTAS
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 08 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Dec 2018 to 1 Jan 2019.
- 20 Dec 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Aug 2018 to 1 Dec 2018.